Clinical Trial Update: Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib as first-line therapy for patients with late-stage non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN